In addition, inhibitors targeting NAT10 (such as remodelin and panobinostat) have shown significant antitumor activity in vivo and in vitro, suggesting that ac4C modification is expected to become a new molecular target for tumor treatment [20, 21]. Here, NAT10 is linked to neoplasm.